International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

Franck Pagès, Bernhard Mlecnik, Florence Marliot, +95

The Lancet

Prognostic BiomarkersOncologyInternational ValidationMedicineImmunology +10

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

Axel Grothey, Alberto Sobrero, Anthony F. Shields, +19

New England Journal of Medicine

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

Jan Franko, Qian Shi, Jeffrey P. Meyers, +16

The Lancet Oncology

Gastrointestinal OncologyIndividual Patient DataMedicineGastroenterologyColorectal Cancer +7

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

Tanios Bekaii‐Saab, Fang‐Shu Ou, Daniel H. Ahn, +17

The Lancet Oncology

Gastrointestinal OncologyMedicineCancer ManagementRegorafenib Dose-optimisationColorectal Cancer +5

Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

Thierry André, Jeffrey A. Meyerhardt, Timothy Iveson, +17

The Lancet Oncology

Gastrointestinal OncologyMedicineCancer ManagementClinical TrialsColorectal Cancer +6

Association of Age With Survival in Patients With Metastatic Colorectal Cancer: Analysis From the ARCAD Clinical Trials Program

Christopher H. Lieu, Lindsay A. Renfro, Aimery de Gramont, +7

Journal of Clinical Oncology

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy

Aziz Zaanan, Qian Shi, Steven R. Alberts, +13

JAMA Oncology

Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas.

Matthew H. G. Katz, Qian Shi, Jeffrey P. Meyers, +15

Journal of Clinical Oncology

Surgical OncologyBr PdacNeoadjuvant TherapyAlliance A021501Cancer Management +17

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project

Katrin Marie Sjoquist, Lindsay A. Renfro, R. John Simes, +29

JNCI Journal of the National Cancer Institute

Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer

Timothy Iveson, Alberto Sobrero, Takayuki Yoshino, +19

Journal of Clinical Oncology